Oncolytic virus play OncoMyx raises $25M series A

Arizona State University spinout OncoMyx raised $25 million in a series A round to develop its oncolytic virus programs in solid cancers.

Boehringer Ingelheim Venture Fund, Delos Capital and Xeraya Capital co-led the tranched financing. Korea Investment Partners, City Hill Ventures and Madison Partners also participated.